Instituição
667 questões de Universidade Federal de São Paulo (UNIFESP), de 2005 a 2021. Cada uma tem página própria, com enunciado completo, alternativas e gabarito — e dá para responder na própria página.
Leia o texto para responder a questão.
The Rise of Antibiotic Resistance
By The Editorial Board
May 10, 2014
The World Health Organization has surveyed the growth of antibiotic-resistant germs around the world – the first such survey it has ever conducted – and come up with disturbing findings. In a report issued late last month, the organization found that antimicrobial resistance in bacteria (the main focus of the report), fungi, viruses and parasites is an increasingly serious threat in every part of the world. “A problem so serious that it threatens the achievements of modern medicine,” the organization said. “A post-antibiotic era, in which common infections and minor injuries can kill, far from being an apocalyptic fantasy, is instead a very real possibility for the 21st century.”
The growth of antibiotic-resistant pathogens means that in ever more cases, standard treatments no longer work, infections are harder or impossible to control, the risk of spreading infections to others is increased, and illnesses and hospital stays are prolonged. All of these drive up the costs of illnesses and the risk of death. The survey sought to determine the scope of the problem by asking countries to submit their most recent surveillance data (114 did so). Unfortunately, the data was glaringly incomplete because few countries track and monitor antibiotic resistance comprehensively, and there is no standard methodology for doing so.
Still, it is clear that major resistance problems have already developed, both for antibiotics that are used routinely and for those deemed “last resort” treatments to cure people when all else has failed. Carbapenem antibiotics, a class of drugs used as a last resort to treat life-threatening infections caused by a common intestinal bacterium, have failed to work in more than half the people treated in some countries. The bacterium is a major cause of hospital-acquired infections such as pneumonia, bloodstream infections, and infections in newborns and intensive-care patients. Similarly, the failure of a last-resort treatment for gonorrhoea has been confirmed in 10 countries, including many with advanced health care systems, such as Australia, Canada, France, Sweden and Britain. And resistance to a class of antibiotics that is routinely used to treat urinary tract infections caused by E. coli is widespread; in some countries the drugs are now ineffective in more than half of the patients treated. This sobering report is intended to kick-start a global campaign to develop tools and standards to track drug resistance, measure its health and economic impact, and design solutions.
The most urgent need is to minimize the overuse of antibiotics in medicine and agriculture, which accelerates the development of resistant strains. In the United States, the Food and Drug Administration (FDA) has issued voluntary guidelines calling on drug companies, animal producers and veterinarians to stop indiscriminately using antibiotics that are important for treating humans on livestock; the drug companies have said they will comply. But the agency, shortsightedly, has appealed a court order requiring it to ban the use of penicillin and two forms of tetracycline by animal producers to promote growth unless they provide proof that it will not promote drug-resistant microbes.
The pharmaceutical industry needs to be encouraged to develop new antibiotics to supplement those that are losing their effectiveness. The Royal Pharmaceutical Society, which represents pharmacists in Britain, called this month for stronger financial incentives. It said that no new class of antibiotics has been discovered since 1987, largely because the financial returns for finding new classes of antibiotics are too low. Unlike lucrative drugs to treat chronic diseases like cancer and cardiovascular ailments, antibiotics are typically taken for a short period of time, and any new drug is apt to be used sparingly and held in reserve to treat patients resistant to existing drugs. Antibiotics have transformed medicine and saved countless lives over the past seven decades. Now, rampant overuse and the lack of new drugs in the pipeline threaten to undermine their effectiveness.
(www.nytimes.com. Adaptado.)
Segundo o texto, a Royal Pharmaceutical Society do Reino Unido afirma queLeia o texto para responder a questão.
The Rise of Antibiotic Resistance
By The Editorial Board
May 10, 2014
The World Health Organization has surveyed the growth of antibiotic-resistant germs around the world – the first such survey it has ever conducted – and come up with disturbing findings. In a report issued late last month, the organization found that antimicrobial resistance in bacteria (the main focus of the report), fungi, viruses and parasites is an increasingly serious threat in every part of the world. “A problem so serious that it threatens the achievements of modern medicine,” the organization said. “A post-antibiotic era, in which common infections and minor injuries can kill, far from being an apocalyptic fantasy, is instead a very real possibility for the 21st century.”
The growth of antibiotic-resistant pathogens means that in ever more cases, standard treatments no longer work, infections are harder or impossible to control, the risk of spreading infections to others is increased, and illnesses and hospital stays are prolonged. All of these drive up the costs of illnesses and the risk of death. The survey sought to determine the scope of the problem by asking countries to submit their most recent surveillance data (114 did so). Unfortunately, the data was glaringly incomplete because few countries track and monitor antibiotic resistance comprehensively, and there is no standard methodology for doing so.
Still, it is clear that major resistance problems have already developed, both for antibiotics that are used routinely and for those deemed “last resort” treatments to cure people when all else has failed. Carbapenem antibiotics, a class of drugs used as a last resort to treat life-threatening infections caused by a common intestinal bacterium, have failed to work in more than half the people treated in some countries. The bacterium is a major cause of hospital-acquired infections such as pneumonia, bloodstream infections, and infections in newborns and intensive-care patients. Similarly, the failure of a last-resort treatment for gonorrhoea has been confirmed in 10 countries, including many with advanced health care systems, such as Australia, Canada, France, Sweden and Britain. And resistance to a class of antibiotics that is routinely used to treat urinary tract infections caused by E. coli is widespread; in some countries the drugs are now ineffective in more than half of the patients treated. This sobering report is intended to kick-start a global campaign to develop tools and standards to track drug resistance, measure its health and economic impact, and design solutions.
The most urgent need is to minimize the overuse of antibiotics in medicine and agriculture, which accelerates the development of resistant strains. In the United States, the Food and Drug Administration (FDA) has issued voluntary guidelines calling on drug companies, animal producers and veterinarians to stop indiscriminately using antibiotics that are important for treating humans on livestock; the drug companies have said they will comply. But the agency, shortsightedly, has appealed a court order requiring it to ban the use of penicillin and two forms of tetracycline by animal producers to promote growth unless they provide proof that it will not promote drug-resistant microbes.
The pharmaceutical industry needs to be encouraged to develop new antibiotics to supplement those that are losing their effectiveness. The Royal Pharmaceutical Society, which represents pharmacists in Britain, called this month for stronger financial incentives. It said that no new class of antibiotics has been discovered since 1987, largely because the financial returns for finding new classes of antibiotics are too low. Unlike lucrative drugs to treat chronic diseases like cancer and cardiovascular ailments, antibiotics are typically taken for a short period of time, and any new drug is apt to be used sparingly and held in reserve to treat patients resistant to existing drugs. Antibiotics have transformed medicine and saved countless lives over the past seven decades. Now, rampant overuse and the lack of new drugs in the pipeline threaten to undermine their effectiveness.
(www.nytimes.com. Adaptado.)
According to the fourth paragraph of the text, the Food and Drug AdministrationLeia o texto para responder a questão.
The Rise of Antibiotic Resistance
By The Editorial Board
May 10, 2014
The World Health Organization has surveyed the growth of antibiotic-resistant germs around the world – the first such survey it has ever conducted – and come up with disturbing findings. In a report issued late last month, the organization found that antimicrobial resistance in bacteria (the main focus of the report), fungi, viruses and parasites is an increasingly serious threat in every part of the world. “A problem so serious that it threatens the achievements of modern medicine,” the organization said. “A post-antibiotic era, in which common infections and minor injuries can kill, far from being an apocalyptic fantasy, is instead a very real possibility for the 21st century.”
The growth of antibiotic-resistant pathogens means that in ever more cases, standard treatments no longer work, infections are harder or impossible to control, the risk of spreading infections to others is increased, and illnesses and hospital stays are prolonged. All of these drive up the costs of illnesses and the risk of death. The survey sought to determine the scope of the problem by asking countries to submit their most recent surveillance data (114 did so). Unfortunately, the data was glaringly incomplete because few countries track and monitor antibiotic resistance comprehensively, and there is no standard methodology for doing so.
Still, it is clear that major resistance problems have already developed, both for antibiotics that are used routinely and for those deemed “last resort” treatments to cure people when all else has failed. Carbapenem antibiotics, a class of drugs used as a last resort to treat life-threatening infections caused by a common intestinal bacterium, have failed to work in more than half the people treated in some countries. The bacterium is a major cause of hospital-acquired infections such as pneumonia, bloodstream infections, and infections in newborns and intensive-care patients. Similarly, the failure of a last-resort treatment for gonorrhoea has been confirmed in 10 countries, including many with advanced health care systems, such as Australia, Canada, France, Sweden and Britain. And resistance to a class of antibiotics that is routinely used to treat urinary tract infections caused by E. coli is widespread; in some countries the drugs are now ineffective in more than half of the patients treated. This sobering report is intended to kick-start a global campaign to develop tools and standards to track drug resistance, measure its health and economic impact, and design solutions.
The most urgent need is to minimize the overuse of antibiotics in medicine and agriculture, which accelerates the development of resistant strains. In the United States, the Food and Drug Administration (FDA) has issued voluntary guidelines calling on drug companies, animal producers and veterinarians to stop indiscriminately using antibiotics that are important for treating humans on livestock; the drug companies have said they will comply. But the agency, shortsightedly, has appealed a court order requiring it to ban the use of penicillin and two forms of tetracycline by animal producers to promote growth unless they provide proof that it will not promote drug-resistant microbes.
The pharmaceutical industry needs to be encouraged to develop new antibiotics to supplement those that are losing their effectiveness. The Royal Pharmaceutical Society, which represents pharmacists in Britain, called this month for stronger financial incentives. It said that no new class of antibiotics has been discovered since 1987, largely because the financial returns for finding new classes of antibiotics are too low. Unlike lucrative drugs to treat chronic diseases like cancer and cardiovascular ailments, antibiotics are typically taken for a short period of time, and any new drug is apt to be used sparingly and held in reserve to treat patients resistant to existing drugs. Antibiotics have transformed medicine and saved countless lives over the past seven decades. Now, rampant overuse and the lack of new drugs in the pipeline threaten to undermine their effectiveness.
(www.nytimes.com. Adaptado.)
According to the text, last resort antibioticsLeia o texto para responder a questão.
The Rise of Antibiotic Resistance
By The Editorial Board
May 10, 2014
The World Health Organization has surveyed the growth of antibiotic-resistant germs around the world – the first such survey it has ever conducted – and come up with disturbing findings. In a report issued late last month, the organization found that antimicrobial resistance in bacteria (the main focus of the report), fungi, viruses and parasites is an increasingly serious threat in every part of the world. “A problem so serious that it threatens the achievements of modern medicine,” the organization said. “A post-antibiotic era, in which common infections and minor injuries can kill, far from being an apocalyptic fantasy, is instead a very real possibility for the 21st century.”
The growth of antibiotic-resistant pathogens means that in ever more cases, standard treatments no longer work, infections are harder or impossible to control, the risk of spreading infections to others is increased, and illnesses and hospital stays are prolonged. All of these drive up the costs of illnesses and the risk of death. The survey sought to determine the scope of the problem by asking countries to submit their most recent surveillance data (114 did so). Unfortunately, the data was glaringly incomplete because few countries track and monitor antibiotic resistance comprehensively, and there is no standard methodology for doing so.
Still, it is clear that major resistance problems have already developed, both for antibiotics that are used routinely and for those deemed “last resort” treatments to cure people when all else has failed. Carbapenem antibiotics, a class of drugs used as a last resort to treat life-threatening infections caused by a common intestinal bacterium, have failed to work in more than half the people treated in some countries. The bacterium is a major cause of hospital-acquired infections such as pneumonia, bloodstream infections, and infections in newborns and intensive-care patients. Similarly, the failure of a last-resort treatment for gonorrhoea has been confirmed in 10 countries, including many with advanced health care systems, such as Australia, Canada, France, Sweden and Britain. And resistance to a class of antibiotics that is routinely used to treat urinary tract infections caused by E. coli is widespread; in some countries the drugs are now ineffective in more than half of the patients treated. This sobering report is intended to kick-start a global campaign to develop tools and standards to track drug resistance, measure its health and economic impact, and design solutions.
The most urgent need is to minimize the overuse of antibiotics in medicine and agriculture, which accelerates the development of resistant strains. In the United States, the Food and Drug Administration (FDA) has issued voluntary guidelines calling on drug companies, animal producers and veterinarians to stop indiscriminately using antibiotics that are important for treating humans on livestock; the drug companies have said they will comply. But the agency, shortsightedly, has appealed a court order requiring it to ban the use of penicillin and two forms of tetracycline by animal producers to promote growth unless they provide proof that it will not promote drug-resistant microbes.
The pharmaceutical industry needs to be encouraged to develop new antibiotics to supplement those that are losing their effectiveness. The Royal Pharmaceutical Society, which represents pharmacists in Britain, called this month for stronger financial incentives. It said that no new class of antibiotics has been discovered since 1987, largely because the financial returns for finding new classes of antibiotics are too low. Unlike lucrative drugs to treat chronic diseases like cancer and cardiovascular ailments, antibiotics are typically taken for a short period of time, and any new drug is apt to be used sparingly and held in reserve to treat patients resistant to existing drugs. Antibiotics have transformed medicine and saved countless lives over the past seven decades. Now, rampant overuse and the lack of new drugs in the pipeline threaten to undermine their effectiveness.
(www.nytimes.com. Adaptado.)
Segundo o texto, o relatório da Organização Mundial da SaúdeLeia o texto para responder a questão.
The Rise of Antibiotic Resistance
By The Editorial Board
May 10, 2014
The World Health Organization has surveyed the growth of antibiotic-resistant germs around the world – the first such survey it has ever conducted – and come up with disturbing findings. In a report issued late last month, the organization found that antimicrobial resistance in bacteria (the main focus of the report), fungi, viruses and parasites is an increasingly serious threat in every part of the world. “A problem so serious that it threatens the achievements of modern medicine,” the organization said. “A post-antibiotic era, in which common infections and minor injuries can kill, far from being an apocalyptic fantasy, is instead a very real possibility for the 21st century.”
The growth of antibiotic-resistant pathogens means that in ever more cases, standard treatments no longer work, infections are harder or impossible to control, the risk of spreading infections to others is increased, and illnesses and hospital stays are prolonged. All of these drive up the costs of illnesses and the risk of death. The survey sought to determine the scope of the problem by asking countries to submit their most recent surveillance data (114 did so). Unfortunately, the data was glaringly incomplete because few countries track and monitor antibiotic resistance comprehensively, and there is no standard methodology for doing so.
Still, it is clear that major resistance problems have already developed, both for antibiotics that are used routinely and for those deemed “last resort” treatments to cure people when all else has failed. Carbapenem antibiotics, a class of drugs used as a last resort to treat life-threatening infections caused by a common intestinal bacterium, have failed to work in more than half the people treated in some countries. The bacterium is a major cause of hospital-acquired infections such as pneumonia, bloodstream infections, and infections in newborns and intensive-care patients. Similarly, the failure of a last-resort treatment for gonorrhoea has been confirmed in 10 countries, including many with advanced health care systems, such as Australia, Canada, France, Sweden and Britain. And resistance to a class of antibiotics that is routinely used to treat urinary tract infections caused by E. coli is widespread; in some countries the drugs are now ineffective in more than half of the patients treated. This sobering report is intended to kick-start a global campaign to develop tools and standards to track drug resistance, measure its health and economic impact, and design solutions.
The most urgent need is to minimize the overuse of antibiotics in medicine and agriculture, which accelerates the development of resistant strains. In the United States, the Food and Drug Administration (FDA) has issued voluntary guidelines calling on drug companies, animal producers and veterinarians to stop indiscriminately using antibiotics that are important for treating humans on livestock; the drug companies have said they will comply. But the agency, shortsightedly, has appealed a court order requiring it to ban the use of penicillin and two forms of tetracycline by animal producers to promote growth unless they provide proof that it will not promote drug-resistant microbes.
The pharmaceutical industry needs to be encouraged to develop new antibiotics to supplement those that are losing their effectiveness. The Royal Pharmaceutical Society, which represents pharmacists in Britain, called this month for stronger financial incentives. It said that no new class of antibiotics has been discovered since 1987, largely because the financial returns for finding new classes of antibiotics are too low. Unlike lucrative drugs to treat chronic diseases like cancer and cardiovascular ailments, antibiotics are typically taken for a short period of time, and any new drug is apt to be used sparingly and held in reserve to treat patients resistant to existing drugs. Antibiotics have transformed medicine and saved countless lives over the past seven decades. Now, rampant overuse and the lack of new drugs in the pipeline threaten to undermine their effectiveness.
(www.nytimes.com. Adaptado.)
Segundo o texto, um dos objetivos do relatório da Organização Mundial da Saúde éLeia o texto para responder a questão.
Healthy choices
How do we reduce waistlines in a country where we traditionally do not like telling individuals what to do?
By Telegraph View
22 Aug 2014
Duncan Selbie, the Chief Executive of Public Health
England, suggests that parents feed their children
from smaller plates. Photo: Alamy
Every new piece of information about Britain’s weight problem makes for ever more depressing reading. Duncan Selbie, the Chief Executive of Public Health England, today tells us that by 2034 some six million Britons will suffer from diabetes. Of course, many people develop diabetes through no fault of their own. But Mr Selbie’s research concludes that if the levels of obesity returned to their 1994 levels, 1.7 million fewer people would suffer from the condition.
Given that fighting diabetes already drains the National Health Service (NHS) by more than £1.5 million, or 10 per cent of its budget for England, the impact upon the Treasury in 20 years’ time from unhealthy lifestyles could be catastrophic. Bad health not only impacts on the individual but also on the rest of the community.
Diagnosis of the challenge is straightforward. The tougher question is what to do about reducing waistlines in a country where we traditionally do not like telling individuals what to do.
It is interesting to note that Mr Selbie does not ascribe to the Big Brother approach of ceaseless legislation and nannying. Rather, he is keen to promote choices – making the case passionately that people should be encouraged to embrace good health. One of his suggestions is that parents feed their children from smaller plates. That way the child can clear his or her plate, as ordered, without actually consuming too much. Like all good ideas, this is rooted in common sense.
(www.telegraph.co.uk. Adaptado.)
Leia o texto para responder a questão.
Healthy choices
How do we reduce waistlines in a country where we traditionally do not like telling individuals what to do?
By Telegraph View
22 Aug 2014
Duncan Selbie, the Chief Executive of Public Health
England, suggests that parents feed their children
from smaller plates. Photo: Alamy
Every new piece of information about Britain’s weight problem makes for ever more depressing reading. Duncan Selbie, the Chief Executive of Public Health England, today tells us that by 2034 some six million Britons will suffer from diabetes. Of course, many people develop diabetes through no fault of their own. But Mr Selbie’s research concludes that if the levels of obesity returned to their 1994 levels, 1.7 million fewer people would suffer from the condition.
Given that fighting diabetes already drains the National Health Service (NHS) by more than £1.5 million, or 10 per cent of its budget for England, the impact upon the Treasury in 20 years’ time from unhealthy lifestyles could be catastrophic. Bad health not only impacts on the individual but also on the rest of the community.
Diagnosis of the challenge is straightforward. The tougher question is what to do about reducing waistlines in a country where we traditionally do not like telling individuals what to do.
It is interesting to note that Mr Selbie does not ascribe to the Big Brother approach of ceaseless legislation and nannying. Rather, he is keen to promote choices – making the case passionately that people should be encouraged to embrace good health. One of his suggestions is that parents feed their children from smaller plates. That way the child can clear his or her plate, as ordered, without actually consuming too much. Like all good ideas, this is rooted in common sense.
(www.telegraph.co.uk. Adaptado.)
Leia o texto para responder a questão.
Healthy choices
How do we reduce waistlines in a country where we traditionally do not like telling individuals what to do?
By Telegraph View
22 Aug 2014
Duncan Selbie, the Chief Executive of Public Health
England, suggests that parents feed their children
from smaller plates. Photo: Alamy
Every new piece of information about Britain’s weight problem makes for ever more depressing reading. Duncan Selbie, the Chief Executive of Public Health England, today tells us that by 2034 some six million Britons will suffer from diabetes. Of course, many people develop diabetes through no fault of their own. But Mr Selbie’s research concludes that if the levels of obesity returned to their 1994 levels, 1.7 million fewer people would suffer from the condition.
Given that fighting diabetes already drains the National Health Service (NHS) by more than £1.5 million, or 10 per cent of its budget for England, the impact upon the Treasury in 20 years’ time from unhealthy lifestyles could be catastrophic. Bad health not only impacts on the individual but also on the rest of the community.
Diagnosis of the challenge is straightforward. The tougher question is what to do about reducing waistlines in a country where we traditionally do not like telling individuals what to do.
It is interesting to note that Mr Selbie does not ascribe to the Big Brother approach of ceaseless legislation and nannying. Rather, he is keen to promote choices – making the case passionately that people should be encouraged to embrace good health. One of his suggestions is that parents feed their children from smaller plates. That way the child can clear his or her plate, as ordered, without actually consuming too much. Like all good ideas, this is rooted in common sense.
(www.telegraph.co.uk. Adaptado.)
Examine o quadrinho para responder a questão.
The Joy of Tech by Nitrozac & Snaggy
Examine o quadrinho para responder a questão.
The Joy of Tech by Nitrozac & Snaggy
Leia o texto para responder a questão.
Cumpridos dez anos de prisão por um crime que não pratiquei e do qual, entanto, nunca me defendi, morto para a vida e para os sonhos: nada podendo já esperar e coisa alguma desejando – eu venho fazer enfim a minha confissão: isto é, demonstrar a minha inocência.
Talvez não me acreditem. Decerto que não me acreditam. Mas pouco importa. O meu interesse hoje em gritar que não assassinei Ricardo de Loureiro é nulo. Não tenho família; não preciso que me reabilitem. Mesmo quem esteve dez anos preso, nunca se reabilita. A verdade simples é esta.
E àqueles que, lendo o que fica exposto, me perguntarem: “Mas por que não fez a sua confissão quando era tempo? Por que não demonstrou a sua inocência ao tribunal?”, a esses responderei: – A minha defesa era impossível. Ninguém me acreditaria. E fora inútil fazer-me passar por um embusteiro ou por um doido… Demais, devo confessar, após os acontecimentos em que me vira envolvido nessa época, ficara tão despedaçado que a prisão se me afigurava uma coisa sorridente. Era o esquecimento, a tranquilidade, o sono. Era um fim como qualquer outro – um termo para a minha vida devastada. Toda a minha ânsia foi pois de ver o processo terminado e começar cumprindo a minha sentença.
De resto, o meu processo foi rápido. Oh! o caso parecia bem claro… Eu nem negava nem confessava. Mas quem cala consente… E todas as simpatias estavam do meu lado.
O crime era, como devem ter dito os jornais do tempo, um “crime passional”. Cherchez la femme*. Depois, a vítima um poeta – um artista. A mulher romantizara-se desaparecendo. Eu era um herói, no fim de contas. E um herói com seus laivos de mistério, o que mais me aureolava. Por tudo isso, independentemente do belo discurso de defesa, o júri concedeu-me circunstâncias atenuantes. E a minha pena foi curta.
Ah! foi bem curta – sobretudo para mim… Esses dez
anos esvoaram-se-me como dez meses. É que, em realidade, as horas não podem mais ter ação sobre aqueles que viveram um instante que focou toda a sua vida.
Atingido o sofrimento máximo, nada já nos faz sofrer. Vibradas as sensações máximas, nada já nos fará oscilar.
Simplesmente, este momento culminante raras são as
criaturas que o vivem. As que o viveram ou são, como eu,
os mortos-vivos, ou – apenas – os desencantados que,
muita vez, acabam no suicídio.
* Cherchez la femme: Procurem a mulher.
(Mário de Sá-Carneiro. A confissão de Lúcio, 2011.)
Leia o texto para responder a questão.
Cumpridos dez anos de prisão por um crime que não pratiquei e do qual, entanto, nunca me defendi, morto para a vida e para os sonhos: nada podendo já esperar e coisa alguma desejando – eu venho fazer enfim a minha confissão: isto é, demonstrar a minha inocência.
Talvez não me acreditem. Decerto que não me acreditam. Mas pouco importa. O meu interesse hoje em gritar que não assassinei Ricardo de Loureiro é nulo. Não tenho família; não preciso que me reabilitem. Mesmo quem esteve dez anos preso, nunca se reabilita. A verdade simples é esta.
E àqueles que, lendo o que fica exposto, me perguntarem: “Mas por que não fez a sua confissão quando era tempo? Por que não demonstrou a sua inocência ao tribunal?”, a esses responderei: – A minha defesa era impossível. Ninguém me acreditaria. E fora inútil fazer-me passar por um embusteiro ou por um doido… Demais, devo confessar, após os acontecimentos em que me vira envolvido nessa época, ficara tão despedaçado que a prisão se me afigurava uma coisa sorridente. Era o esquecimento, a tranquilidade, o sono. Era um fim como qualquer outro – um termo para a minha vida devastada. Toda a minha ânsia foi pois de ver o processo terminado e começar cumprindo a minha sentença.
De resto, o meu processo foi rápido. Oh! o caso parecia bem claro… Eu nem negava nem confessava. Mas quem cala consente… E todas as simpatias estavam do meu lado.
O crime era, como devem ter dito os jornais do tempo, um “crime passional”. Cherchez la femme*. Depois, a vítima um poeta – um artista. A mulher romantizara-se desaparecendo. Eu era um herói, no fim de contas. E um herói com seus laivos de mistério, o que mais me aureolava. Por tudo isso, independentemente do belo discurso de defesa, o júri concedeu-me circunstâncias atenuantes. E a minha pena foi curta.
Ah! foi bem curta – sobretudo para mim… Esses dez
anos esvoaram-se-me como dez meses. É que, em realidade, as horas não podem mais ter ação sobre aqueles que viveram um instante que focou toda a sua vida.
Atingido o sofrimento máximo, nada já nos faz sofrer. Vibradas as sensações máximas, nada já nos fará oscilar.
Simplesmente, este momento culminante raras são as
criaturas que o vivem. As que o viveram ou são, como eu,
os mortos-vivos, ou – apenas – os desencantados que,
muita vez, acabam no suicídio.
* Cherchez la femme: Procurem a mulher.
(Mário de Sá-Carneiro. A confissão de Lúcio, 2011.)
Observe as passagens do texto:
No contexto em que estão empregados, os termos em
destaque significam, respectivamente,
Leia o texto para responder a questão.
Cumpridos dez anos de prisão por um crime que não pratiquei e do qual, entanto, nunca me defendi, morto para a vida e para os sonhos: nada podendo já esperar e coisa alguma desejando – eu venho fazer enfim a minha confissão: isto é, demonstrar a minha inocência.
Talvez não me acreditem. Decerto que não me acreditam. Mas pouco importa. O meu interesse hoje em gritar que não assassinei Ricardo de Loureiro é nulo. Não tenho família; não preciso que me reabilitem. Mesmo quem esteve dez anos preso, nunca se reabilita. A verdade simples é esta.
E àqueles que, lendo o que fica exposto, me perguntarem: “Mas por que não fez a sua confissão quando era tempo? Por que não demonstrou a sua inocência ao tribunal?”, a esses responderei: – A minha defesa era impossível. Ninguém me acreditaria. E fora inútil fazer-me passar por um embusteiro ou por um doido… Demais, devo confessar, após os acontecimentos em que me vira envolvido nessa época, ficara tão despedaçado que a prisão se me afigurava uma coisa sorridente. Era o esquecimento, a tranquilidade, o sono. Era um fim como qualquer outro – um termo para a minha vida devastada. Toda a minha ânsia foi pois de ver o processo terminado e começar cumprindo a minha sentença.
De resto, o meu processo foi rápido. Oh! o caso parecia bem claro… Eu nem negava nem confessava. Mas quem cala consente… E todas as simpatias estavam do meu lado.
O crime era, como devem ter dito os jornais do tempo, um “crime passional”. Cherchez la femme*. Depois, a vítima um poeta – um artista. A mulher romantizara-se desaparecendo. Eu era um herói, no fim de contas. E um herói com seus laivos de mistério, o que mais me aureolava. Por tudo isso, independentemente do belo discurso de defesa, o júri concedeu-me circunstâncias atenuantes. E a minha pena foi curta.
Ah! foi bem curta – sobretudo para mim… Esses dez
anos esvoaram-se-me como dez meses. É que, em realidade, as horas não podem mais ter ação sobre aqueles que viveram um instante que focou toda a sua vida.
Atingido o sofrimento máximo, nada já nos faz sofrer. Vibradas as sensações máximas, nada já nos fará oscilar.
Simplesmente, este momento culminante raras são as
criaturas que o vivem. As que o viveram ou são, como eu,
os mortos-vivos, ou – apenas – os desencantados que,
muita vez, acabam no suicídio.
* Cherchez la femme: Procurem a mulher.
(Mário de Sá-Carneiro. A confissão de Lúcio, 2011.)
Analise a capa de um folder de uma campanha de trânsito.
Explicitando-se os complementos dos verbos em “Eu
cuido, eu respeito.”, obtém-se, em conformidade com a
norma-padrão da língua portuguesa:
Leia o texto para responder a questão.
Você conseguiria ficar 99 dias sem o Facebook?
Uma organização não governamental holandesa está propondo um desafio que muitos poderão considerar impossível: ficar 99 dias sem dar nem uma “olhadinha” no Facebook. O objetivo é medir o grau de felicidade dos usuários longe da rede social.
O projeto também é uma resposta aos experimentos psicológicos realizados pelo próprio Facebook. A diferença neste caso é que o teste é completamente voluntário. Ironicamente, para poder participar, o usuário deve trocar a foto do perfil no Facebook e postar um contador na rede social.
Os pesquisadores irão avaliar o grau de satisfação e felicidade dos participantes no 33.º dia, no 66.º e no último dia da abstinência.
Os responsáveis apontam que os usuários do Facebook gastam em média 17 minutos por dia na rede social. Em 99 dias sem acesso, a soma média seria equivalente a mais de 28 horas, que poderiam ser utilizadas em “atividades emocionalmente mais realizadoras”.
(http://codigofonte.uol.com.br. Adaptado.)
Considere os enunciados a seguir para responder a questão.
• [...] ficar 99 dias sem dar nem uma “olhadinha” no Facebook. (1.º parágrafo)
• [...] que poderiam ser utilizadas em “atividades emocionalmente mais realizadoras”. (4.º parágrafo)
